TherapeuticsMD, Inc. Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount
TherapeuticsMD, Inc. (TXMD) reported Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount of -$137.00 thousand for the 12-month period ending 2025-12-31, per its 10-K/A filed 2026-04-01.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate · last filed 2026-04-01
- TherapeuticsMD, Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2025 was -$137.00K.
- TherapeuticsMD, Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2024 was -$492.00K.
- TherapeuticsMD, Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2023 was -$1.63M.
| Period end | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month |
|---|---|
| 2025-12-31 | -$137.00K 10-K/A · filed 2026-04-01 |
| 2024-12-31 | -$492.00K 10-K/A · filed 2026-04-01 |
| 2023-12-31 | -$1.63M 10-K · filed 2024-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |